LCZ696

Showing 5 posts of 5 posts found.

Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

Novartis image

Novartis wins US nod for new heart drug

July 8, 2015
Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril

The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …

Novartis image

Novartis heart drug steps closer to EAMS scheme

April 23, 2015
Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan

Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …

fda

FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill

February 16, 2015
Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid

The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review.  Lenvima …

Novartis heart drug sees stellar results

September 1, 2014
Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan

Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …

Latest content